Business
Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral presentation to
About this update from Terns Pharmaceuticals, Inc.
[{"type":"text","content":"Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial Cash, cash equivalents and marketable securities of $295 million, expected to provide runway into 2028 FOSTER CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today reported financial results for the third quarter ended September 30, 2025, and provided corporate updates. “We’re thrilled with the positive momentum of the CARDINAL program generated by the unprecedented Phase 1 MMR achievement rate and encouraging safety/tolerability profile published in the recent ASH abstract. These data continue to reinforce our view of the potential of TERN-701 to become a best-in-disease treatment for patients with chronic myeloid leukemia (CML),” said Amy Burroughs, chief executive officer of Terns Pharmaceuticals. “Our team continues to execute with precision and focus towards an updated and expanded CARDINAL readout at ASH, with an ultimate goal of bringing this important new therapy to CML patients.” Recent Pipeline Developments and Anticipated Milestones TERN-701: Novel investigational allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia (CML) In November 2025, Terns announced that an abstract with updated data from the ongoing Phase 1 CARDINAL trial evaluating TERN-701 in patients with relapsed/refractory CML had been selected for oral presentation at the 67th ASH Annual Meeting and ExpositionThe abstract reported data from the ongoing dose escalation and dose expansion parts of the CARDINAL trial. Highlights include from the abstract include: Overall (cumulative) major molecular response (MMR) rate of 75% by 24 weeks, with 64% achieving MMR and 100% maintaining MMROverall (cumulative) MMR by 24 weeks in difficult to treat patient subgroups 69% in patients with lack of efficacy to last tyrosine kinase inhibitor (TKI)60% in patients who had prior asciminib67% in patients with prior asciminib / ponatinib / investigational TKI No patients had lost MMR at the time of data cutoffEncouraging safety and tolerability profile at all doses evaluated A more expansive and updated dataset from the CARDINAL trial will be presented at ...